arrow
B

Bor-Sheng Ko

National Cheng Kung University
H指数:42
被引数:6,886

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms/syndromes and acute myeloid leukemia undergoing allogeneic transplantation

移植早期分子残留病灶可预测接受异基因移植的骨髓增生异常肿瘤/综合征和急性髓系白血病的结局

2026-10-010
OAAI
Joint position statement of the diagnosis and management of light chain amyloidosis and light chain cardiac amyloidosis by the Taiwan Society of Cardiology (TSOC) and the Hematology Society of Taiwan (HST)

台湾心脏学会(TSOC)和台湾血液学会(HST)关于轻链淀粉样变性及轻链心脏淀粉样变性的诊断与管理的联合立场声明

2026-08-010
OAAI
Response to comment on “Daratumumab, lenalidomide, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma: A real-world propensity score-matched study”

对“达雷珠单抗、来那度胺和地塞米松与达雷珠单抗、硼替佐米和地塞米松在复发性和难治性多发性骨髓瘤中的应用:一项真实世界倾向性评分匹配研究”的评论回复

2026-06-060
OAAI
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data

高强度治疗急性髓系白血病中伴随发生的FLT3突变在分子亚组间的预后影响:来自真实世界基因组数据的见解

2026-01-060
OAAI
The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

年龄对初诊多发性骨髓瘤患者自体造血细胞移植后生存和超额死亡率的影响

2026-01-011
OA
Consensus of the Hematology Society of Taiwan on the management of paroxysmal nocturnal hemoglobinuria (PNH)

中华血液学会关于阵发性睡眠性血红蛋白尿症(PNH)管理的共识

2025-10-280
OAAI
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Nivolumab联合ipilimumab治疗潜在可切除的肝细胞癌:长期疗效与生物标志物探索

2025-09-170
PREAI
Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM)

台湾慢性肺移植物抗宿主病共识:台湾血液与骨髓移植学会(TBMT)和台湾胸腔与重症医学学会(TSPCCM)联合声明

2025-09-090
OAAI
Molecular Milestones and Survival Outcomes of Ponatinib Treatment in Patients With Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia: A Real-World Analysis

分子里程碑与生存结局:Ponatinib治疗慢性髓性白血病和费城染色体阳性急性淋巴细胞白血病的真实世界分析

2025-09-020
PRE
Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study

真实世界证据:罗培干扰素α-2b在骨髓增殖性肿瘤患者中的疗效与安全性研究:一项回顾性队列研究

2025-06-250
PRE
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

AML和DNMT3A突变患者临床结局的基因组学和转录组学决定因素

2025-05-200
OA
Clinical Features and Prognostic Implications of BCMA, BAFF, and APRIL Expression in Acute Myeloid Leukemia

BCMA、BAFF和APRIL表达在急性髓系白血病中的临床特征及预后意义

BLOOD
IF23.1
2024-11-050
PRE
Characteristics and Long-Term Efficacy of 25 Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab or Ravulizumab in Taiwan

25例接受依库珠单抗或拉尼珠单抗治疗的阵发性夜间血红蛋白尿患者的特征及长期疗效(台湾地区)

BLOOD
IF23.1
2024-11-050
PRE
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)
2024-08-193
OAAI